Nektar ($NKTR) REZOLVE-AA Trial Enrollment and Eligibility Violations Case

Investors can submit applications for the lead plaintiff role.

N.D. California

Court

5:26-cv-01951

Case number

02/26/2025

Class period Start

12/15/2025

Class period End

05/05/2026

Lead Plaintiff motion deadline

$NKTR investors filed a claim against Nektar for allegedly misrepresenting that its REZOLVE-AA alopecia areata trial was enrolled according to protocol when ineligible patients were included.
After Nektar disclosed that its Phase 2b REZOLVE-AA trial missed statistical significance and said four ineligible patients had been included, $NKTR fell 7.8% on December 16, 2025, closing at $49.16 per share.
$NKTR investors can join this case to be notified about potential recovery.
Case Details:

Between February 26, 2025, and December 15, 2025, Nektar told investors its Phase 2b REZOLVE-AA trial for rezpegaldesleukin in alopecia areata had been enrolled under the study’s stated standards. Executives emphasized the company’s drug-development expertise, its efforts to minimize clinical risk, and that patients had to meet specific eligibility rules, including severe-to-very-severe disease and other screening requirements.

However, during this period, investors allege the trial was not enrolled according to those rules and that this undermined the study’s results. Nektar allegedly failed to disclose that REZOLVE-AA included patients who should not have been allowed into the trial, that those enrollment problems were likely to hurt the study’s outcome, and that the trial’s integrity and prospects were therefore overstated.

Then, on December 16, 2025, the company revealed topline results showing the REZOLVE-AA trial missed statistical significance and said four patients should have been disqualified from randomization. $NKTR fell $4.14, closing at $49.16. 

Additional revelations followed on December 16, 2025, including that two patients had unstable alopecia areata diagnosed less than six months before randomization and two others began treatment before completing the required 8-week washout for prior alopecia areata medications. 

By December 16, 2025, shares had dropped to $49.16, representing a total decline of 7.8% over the correction period.

Based on these events, $NKTR investors filed a claim against Nektar, alleging the company:
It broke the trial’s own enrollment rules.
It gave investors an overly positive picture of the REZOLVE-AA trial and its prospects.
It caused investors to buy at inflated prices before the market reacted to the truth.
Investors argue Nektar misled the market about the integrity of the REZOLVE-AA trial and its likelihood of success, causing losses when the truth emerged.

Case Type

US Securities Class Action

Case Status

Lead Plaintiff Submission

Alleged Offence

Misleading Statements,

Fraud,

Failure to Disclose,

Omissions

Suspected Party

Directors,

Management

Security Type

Stocks

Trade Direction

Long

Shock Event Date

12/16/2025

Filing date

03/06/2026

Lead Plaintiff Deadline

05/05/2026

Trusted by industry leaders

Endorsed by top professionals who trust our innovative solutions to drive impactful results.